Previous 10 | Next 10 |
home / stock / oryzf / oryzf news
CBO joins from AIG Asset Management To lead global business strategy and US corporate initiatives from US base MADRID, Spain and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmac...
Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disorders MADRID, Spain and CAMBRIDGE, Mass...
Iadademstat consistently stronger in viability reduction in AML & SCLC cells Superior target engagement at low concentration in AML & SCLC cells Superior disruption of the Snag-domain protein-protein interactions MADRID, Spain and CAMBRIDGE, Mass....
Jefferies London Healthcare Conference 2021 Evercore ISI 4th Annual HealthCONx Conference 2021 63 th American Society of Hematology 2021 Congress (ASH-2021) MADRID, Spain and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...
MADRID, Spain and CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for...
PORTICO already recruiting in several European countries MADRID, Spain and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases...
Long-term vafidemstat treatment was safe and well tolerated with drug exposures up to 2 years Anti-inflammatory activity observed in vafidemstat-treated patients SATEEN was a pilot, small scale, trial not powered to get definitive efficacy data MADRID, Spain and ...
International Conference on Autism ICA-2021 BIO-Spain 2021 34th European College Neuropsychopharmacology (ECNP) congress 2021 21st Sachs Annual Biotech in Europe Forum 2021 37th Congress of the European Committe for Treatment and Research in Multiple Scle...
HOPE will be the first clinical trial in precision medicine with vafidemstat in neurodevelopmental diseases Multicentric study to assess the efficacy of vafidemstat in Kabuki syndrome patients Expected to start in early 2022 In collaboration with the ...
Oryzon Genomics S.A. (OTCPK:ORYZF): Q2 GAAP EPS of $0.02. Cash and equivalents of $40.08M. Press Release For further details see: Oryzon Genomics S.A. reports Q2 results
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...